Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8699708 | 1.00 | IDO1 (0.49) | IDO1BLMTSHRHTTALDH1A1 | |
| SCHEMBL29663637 | 1.00 | IDO1 (0.49) | IDO1BLMTSHRHTTALDH1A1 | |
| SCHEMBL9159890 | 1.00 | IDO1 (0.49) | IDO1BLMTSHRHTTALDH1A1 | |
| SCHEMBL9722657 | 0.94 | IDO1 (0.43) | IDO1BLMTSHRHTTALDH1A1 | |
| SCHEMBL9165650 | 0.88 | IDO1 (0.46) | IDO1RETHTR2A | |
| SCHEMBL21937667 | 0.88 | IDO1 (0.46) | IDO1RETHTR2A | |
| SCHEMBL384149 | 0.88 | IDO1 (0.46) | IDO1RETHTR2A | |
| Fluoride SCHEMBL29683041 | 0.86 | IDO1 (0.44) | IDO1RETHTR2A | |
| SCHEMBL1567118 | 0.81 | IDO1 (0.49) | IDO1HTTALDH1A1CYP2D6LMNA | |
| SCHEMBL6723016 | 0.81 | IDO1 (0.49) | IDO1HTTALDH1A1GID4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925530-B | 3, 4-dihydronaphthalene-1 (2H) -one compound, preparation method and application | 滨州医学院 | 2024-03-12 | — | — | CN | claimed |
| CN-115925530-A | 3,4-dihydronaphthalene-1 (2H) -ketone compound, preparation method and application | 滨州医学院 | 2023-04-07 | — | — | CN | claimed |
| CN-111018692-A | Method for preparing 1,2,3, 4-tetrahydro-1-naphthoic acid by super-strong alkali method | 安庆博曼生物技术有限公司 | 2020-04-17 | — | — | CN | claimed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | claimed |
| CN-1839116-B | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL CO | 2010-05-26 | — | — | CN | claimed |
| JP-4361566-B2 | — | — | 2009-11-11 | — | — | JP | claimed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | claimed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | claimed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | claimed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | claimed |
| CN-1839116-A | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL CO (JP) | 2006-09-27 | — | — | CN | claimed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | claimed |
| EP-0497976-B9 | METHOD OF PRODUCING ACETALS | NEW JAPAN CHEM CO LTD (JP) | 2005-01-12 | — | — | EP | claimed |
| EP-0856515-B1 | Method of making acetals | MILLIKEN & CO (US) | 2001-12-05 | — | — | EP | claimed |
| EP-0856515-A1 | Method of making acetals | MILLIKEN RESEARCH CORPORATION (US) | 1998-08-05 | — | — | EP | claimed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | claimed |
| US-5731474-A | Method of making acetals | MILLIKEN RESEARCH CORPORATION (US) | 1998-03-24 | — | — | US | claimed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| EP-0497976-B1 | METHOD OF PRODUCING ACETALS | NEW JAPAN CHEM CO LTD (JP) | 1996-09-11 | — | — | EP | claimed |
| EP-0497976-A1 | METHOD OF PRODUCING ACETALS | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1992-08-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | IDO1 948/4885BLM 3524/4885TSHR 515/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | IDO1 905/4885BLM 3540/4885TSHR 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.